Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network
Scientific Reports · 2024
DOI: 10.1038/s41598-024-52016-4 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Scientific Reports, 2024. Verfasst von Guillaume Larid und 12 weiteren Autor:innen. Beteiligte Einrichtung: LITEC, Université de Poitiers, CHU Poitiers, 86000, Poitiers, France. guillaume.larid@chu-poitiers.fr. Hauptthemen laut MEDLINE: Antirheumatic Agents, Axial Spondyloarthritis, Spondylarthritis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MSD France.
Abstract (Originalsprache)
The objectives of our study were to assess retention rate, safety, and predictive factors for retention of subcutaneous (SC) TNF inhibitors (TNFi) (adalimumab (ADA), etanercept (ETN), golimumab (GOL), and certolizumab pegol (CZP)) in axial spondyloarthritis (axSpA) depending on the line of treatment in real-life conditions. A multicentre retrospective observational study was conducted including 552 patients fulfilling the ASAS criteria for axSpA followed in the RIC-France register who began SC-TNFi between 01/01/13 and 08/31/2018 for a total of 824 prescriptions. Taking all lines of treatment into account, GOL had a significantly higher retention rate compared with ADA, ETN, and CZP with a mean retention length of 59 months. As first-line bDMARDs, GOL had a significantly higher retention rate compared with ADA and ETN. ETN had the best retention rate when prescribed as at least 3rd bDMARD. Taking all lines of treatment into account, female sex, peripheral disease, BASDAI at initiation, and line of treatment were predictive factors for treatment cessation. Primary inefficiency was the most frequent reason for treatment cessation. In conclusion, GOL showed the highest retention rate in axSpA. Male sex, absence of peripheral disease, and early line of prescription were associated with better SC-TNFi retention in axSpA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- LITEC, Université de Poitiers, CHU Poitiers, 86000, Poitiers, France. guillaume.larid@chu-poitiers.fr.
- Private Practice, Valenciennes, France.
- CHU Poitiers, Poitiers, France.
- Bethune Hospital Center, Bethune, France.
- University Hospital of Amiens-Picardie, Amiens, France.
- Hôpital Victor Provo, Hospital of Roubaix, Roubaix, France.
ORCID-Profile: Guillaume Larid, Elisabeth Gervais
Förderung
- MSD France
Zitieren
APA
Larid, G., Baudens, G., Tiemdjo-Djimaffo, G., Coquerelle, P., Goeb, V., Guyot, M. H., Marguerie, L., Maury, F., Veillard, E., Houvenagel, E., Salmon, J. H., Flipo, R. M., & Gervais, E. (2024). Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network. Scientific Reports. https://doi.org/10.1038/s41598-024-52016-4
Vancouver
Larid G, Baudens G, Tiemdjo-Djimaffo G, Coquerelle P, Goeb V, Guyot MH, et al. Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network. Scientific Reports. 2024. doi:10.1038/s41598-024-52016-4
BibTeX
@article{Larid2024,
author = {Larid, Guillaume and Baudens, Guy and Tiemdjo-Djimaffo, Georges and Coquerelle, Pascal and Goeb, Vincent and Guyot, Marie Hélène and Marguerie, Laurent and Maury, Frédéric and Veillard, Eric and Houvenagel, Eric and Salmon, Jean-Hugues and Flipo, René-Marc and Gervais, Elisabeth},
title = {Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network},
journal = {Scientific Reports},
year = {2024},
doi = {10.1038/s41598-024-52016-4}
}
EUVIMED